We reported that 88.9% of patients with invasive stage I-II cancer and negative axillary lymph nodes (not candidate to neo-adjuvant therapy) underwent a sentinel node biopsy; 71.4% of patients with invasive stage I-II cancer were treated with adjuvant therapy after conservative surgery; 74.4% of patients started adjuvant therapy within ≤ 8 weeks; adjuvant endocrine therapy (alone or in combination with an anti-HER2 agent) was administered to 100% (952 out of 952) of patients with HR-positive disease. The gene discussed is ERBB2; the disease is cancer.